On June 13, 2024, the Board of Directors approved a share buyback authorization, commencing on June 17, 2024, for the purchase of up to $200.0 million of the Company’s outstanding common stock through June 17, 2026 (the “2024 Buyback Authorization”). No shares have been purchased under the 2024 Buyback Authorization. As of January 31, 2026, the dollar value of shares that remained available to be purchased by the Company under 2024 Buyback Authorization was $200.0 million.

The Company paid dividends totaling $1.8 million and $5.3 million in the three months ended January 31, 2026 and February 1, 2025, respectively. The Company paid dividends totaling $6.5 million and $15.3 million in the nine months ended January 31, 2026 and February 1, 2025, respectively. Dividends paid for dividend equivalent payments on restricted stock units that vested in the three months ended January 31, 2026 were less than $0.1 million and were $0.6 million in the three months ended February 1, 2025. Dividends paid for dividend equivalent payments on restricted stock units that vested in the nine months ended January 31, 2026 and February 1, 2025 were $0.5 million and $0.8 million, respectively.

Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. A summary of changes in AOCI(L), net of tax is shown below:


	Three Months Ended January 31, 2026 (13 Weeks)									Nine Months Ended January 31, 2026 (39 Weeks)
(in millions)	Currency translation adjustments			Derivative instruments			Total			Currency translation adjustments			Derivative instruments			Total
Balance at beginning of period	$	(21.7	)	$	(0.6	)	$	(22.3	)	$	(28.2	)	$	(1.6	)	$	(29.8	)
Other comprehensive income (loss)		11.7			0.6			12.3			18.2			2.0			20.2
Tax (expense) benefit		(0.4	)		(0.1	)		(0.5	)		(0.4	)		(0.5	)		(0.9	)
Net other comprehensive income (loss)		11.3			0.5			11.8			17.8			1.5			19.3
Balance at the end of period	$	(10.4	)	$	(0.1	)	$	(10.5	)	$	(10.4	)	$	(0.1	)	$	(10.5	)


	Three Months Ended February 1, 2025 (13 Weeks)									Nine Months Ended February 1, 2025 (40 Weeks)
(in millions)	Currency translation adjustments			Derivative instruments			Total			Currency translation adjustments			Derivative instruments			Total
Balance at beginning of period	$	(34.9	)	$	(2.8	)	$	(37.7	)	$	(36.5	)	$	(0.2	)	$	(36.7	)
Other comprehensive income (loss)		(13.3	)		2.7			(10.6	)		(12.5	)		(0.8	)		(13.3	)
Tax (expense) benefit		(2.2	)		(0.7	)		(2.9	)		(1.4	)		0.2			(1.2	)
Net other comprehensive income (loss)		(15.5	)		2.0			(13.5	)		(13.9	)		(0.6	)		(14.5	)
Balance at the end of period	$	(50.4	)	$	(0.8	)	$	(51.2	)	$	(50.4	)	$	(0.8	)	$	(51.2	)

The Company has granted restricted stock awards (“RSAs”), restricted stock units (“RSUs”), performance stock units (“PSUs”) and stock awards to employees and non-employee directors under its long-term incentive compensation plans.

During the nine months ended January 31, 2026, the Company granted 833,640 PSUs to certain employees. The PSUs may be earned on the third anniversary of the grant date based on a cumulative three-year performance period relative to established goals for threshold and target performance. The performance measures are based on return on invested capital (“ROIC”) and annualized total

stockholder return (“TSR”) measures, in each case through the end of the Company’s fiscal year ending April 29, 2028, with 60% of the award allocated to the ROIC measure and 40% to the TSR measure. The PSUs earn dividend equivalents during the vesting periods, which are forfeitable if the PSUs do not vest.

The fair value of the PSUs based on an ROIC measure (“ROIC PSUs”) is based on the closing stock price on the date of grant. Compensation expense is recognized when it is probable that the target performance criteria will be achieved. The Company assesses the probability of vesting at each balance sheet date and adjusts compensation expense based on the probability assessment. Based on the Company’s current projections, no compensation expense has been recognized for the ROIC PSUs to date, as the performance conditions are not probable of being met.

The Company estimated the grant date fair value of its PSUs based on a TSR performance measure using a Monte Carlo simulation model, as the TSR metric and changes in stock price are considered market conditions under ASC 718, “Compensation - Stock Compensation.” Compensation expense is recognized ratably over the performance period based on the awards grant date fair value.

As of January 31, 2026, unrecognized share-based compensation expense for the PSUs was $3.5 million, which is expected to be recognized over a weighted average period of approximately 2.0 years.

RSUs granted vest over a pre-determined period of time, up to five years from the date of grant. The fair value of the RSUs granted are based on the closing stock price on the date of grant and earn dividend equivalents during the vesting periods, which are forfeitable if the RSUs do not vest. Awards subject to graded vesting are recognized using the accelerated recognition method over the requisite service period. The following table summarizes RSU activity:

As of January 31, 2026, unrecognized share-based compensation expense for RSUs was $5.7 million which will be recognized over a weighted-average amortization period of 1.5 years.

The Company grants stock awards to its non-employee directors as a component of their compensation. The stock awards vest immediately upon grant. Prior to December 2025, non-employee directors could have elected to defer receipt of their shares under the Company’s non-qualified deferred compensation plan. During the third quarter of fiscal year 2026, the Company terminated its deferred compensation plan and it is expected to be fully liquidated by January 2027.

The following table summarizes awards granted to non-employee directors:


	Non-employee director awards			Deferred non-employee director awards			Total			Weighted average grant date fair value
Outstanding at May 3, 2025		—			147,312			147,312		$	22.39
Awarded		55,629			58,695			114,324		$	7.52
Issued		(55,629	)		(11,140	)		(66,769	)	$	10.33
Non-vested at January 31, 2026		—			194,867			194,867		$	17.80

As of May 3, 2025, the Company had 710,349 RSAs outstanding which were subject to the achievement of an EBITDA measure for fiscal 2025. The EBITDA performance measure for fiscal 2025 was not met and the outstanding RSAs were cancelled in June 2025.

All stock-based awards to employees and non-employee directors are recognized in selling and administrative expenses on the condensed consolidated statements of operations. The table below summarizes the stock-based compensation expense related to the equity awards:


	Three Months Ended				Nine Months Ended
	January 31, 2026		February 1, 2025		January 31, 2026		February 1, 2025
(in millions)	(13 Weeks)		(13 Weeks)		(39 Weeks)		(40 Weeks)
RSUs	$	1.2	$	1.5	$	3.8	$	3.5
PSUs		0.5		0.3		1.2		0.5
Deferred non-employee director awards		—		—		0.4		0.9
Non-employee director awards		—		—		0.5		0.6
Total stock-based compensation expense	$	1.7	$	1.8	$	5.9	$	5.5